Importance of Published Article
Alzheimer's disease (AD) is a complex, multifactorial disease. It has been difficult to develop a biomarker to closely link preclinical AD status with continuous disease development to accurately predict progressive AD trajectories, given the condition that the insidious disease onset often takes decades. Built on the advancement of the event-based probabilistic model in AD research [3] , we integrated the 10 available AD biomarkers to calibrate the temporal sequence of events that occur during the AD developmental continuum. Our findings in the article "Staging Alzheimer's Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers" [1] demonstrated that the abnormal functional connectivity events in the hippocampus network and the default mode network are the "upstream" factors that occur before the abnormal A␤ and p-tau level events occur in the cerebrospinal fluid, supporting the network dysfunction hypothesis of AD. Using the 10 sequential numeric scores, we created an index-termed the characterizing Alzheimer's disease risk events, or "CARE," index-to characterize risks associated with AD stages and quantify disease severity on an individual subject basis. The CARE index constructed the main framework for biology-based AD stages and demonstrated that clinically diagnosed mild cognitive impairment subjects are biologically heterogeneous and are distributed across the AD continuum. We believe the CARE index will have wide clinical applications. If the Editorial temporal course of disease progression is consistent with biomarker-defined events in individuals, we will have a crucial window of opportunity to intervene with disease-modifying therapy. The CARE index will facilitate clinical trials by selecting the right segmentation of patient populations based on their disease stages to enrich the response rate and statistical power; it can also be used to monitor and evaluate treatment efficacy through changes in stage status in individual subjects.
